NIFTY 50

WHO rejects antiviral drug Remdesivir as COVID treatment; here’s how it will impact treatment in India

Updated : November 20, 2020 20:14:57 IST

In a crucial development for hospitals and COVID-19 patients, the World Health Organisation (WHO) has rejected antiviral drug Remdesivir as a COVID treatment. After conducting several trials, the WHO found that the drug did not improve survival rates for patients nor did it help them recover.

Gilead, the manufacturer of Remdesivir said it is disappointed with WHOs recommendation against the drug. The company has reiterated that the drug does help in faster recovery and is being used across 50 countries to treat the deadly virus.

As many Indian hospitals continue to rely on Remdesivir as the treatment for COVID-19, CNBC-TV18’s Archana Shukla gives details on how this will impact the treatment in India.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you